Divis Laboratories is currently trading at Rs. 1732.95, up by 75.15 points or 4.53% from its previous closing of Rs. 1657.80 on the BSE.
The scrip opened at Rs. 1661.95 and has touched a high and low of Rs. 1742.90 and Rs. 1627.15 respectively. So far 38361 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1776.15 on 27-Oct-2019 and a 52 week low of Rs. 1421.00 on 30-Nov-2018.
Last one week high and low of the scrip stood at Rs. 1742.90 and Rs. 1627.15 respectively. The current market cap of the company is Rs. 45679.18 crore.
The promoters holding in the company stood at 52.01%, while Institutions and Non-Institutions held 35.07% and 12.92% respectively.
Divi’s Laboratories’ Unit-I facility at Lingojigudem, Bhuvanagiri Yadadri District, Telangana has been inspected by the US Food and Drug Administration (USFDA) from the November 11, 2019 to November 15, 2019. This inspection was a general cGMP inspection by the USFDA. The inspection has been concluded with no 483 observations.
Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.